William Blair initiated coverage of Compass Therapeutics (CMPX) with an Outperform rating and no price target The firm cites the potential success of the company’s lead program tovecimig in patients with previously treated biliary tract cancer for the Outperform rating. Following positive top-line results on objective response rate, clinical outcome secondary endpoints are on track for disclosure at the end of Q1, when positive progression-free survival results will support regulatory filings with the FDA, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPX:
- Compass Therapeutics: Emerging Bispecific Portfolio Positions Tovecimig to Redefine Second-Line Biliary Tract Cancer Standard of Care
- High-Conviction Buy on Compass Therapeutics: Near-Term Tovecimig Registration Data and Differentiated PD-1 x PD-L1 Bispecific Drive Favorable Risk-Reward
- Compass Therapeutics files $400M mixed securities shelf
- Promising Clinical Data and Market Positioning Drive Buy Rating for Compass Therapeutics
- Canaccord starts Compass Therapeutics with a Buy ahead of tovecimig readout